Skip to main content

Perrigo Company plc (PRGO) Stock Analysis

Recovery setup

SellVALUE-TRAP 3/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $11.41: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including... Read more

Stop $10.64Target $14.45(analyst − 15%)A.R:R 2.9:1
Analyst target$17.00+49.0%4 analysts
$14.45our TP
$11.41price
$17.00mean
$20

Sell if holding. Engine safety override at $11.41: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 61. Score 5.3/10, moderate confidence.

Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.7 < 4.0)
Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap)

Key Metrics

P/E (TTM)
P/E (Fwd)4.7
Mkt Cap$1.6B
EV/EBITDA7.2
Profit Mgn-33.5%
ROE-38.7%
Rev Growth-2.5%
Beta0.49
Dividend10.27%
Rating analysts10

Quality Signals

Piotroski F6/9

Options Flow

P/C0.02bullish
IV91%elevated
Max Pain$28+141.0% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·1 ceiling hit

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
0.4
Growth Rank
0.7
Value Rank
8.6

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Support Resistance
4.0
Bollinger
4.4

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Rsi
3.9
Ma Position
6.0
Macd
6.7
Volume distribution (falling OBV)Below 200-MA, MA slope -11.9%/30d — confirmed downtrend

Unprofitable operations — net margin -33.5%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Roa
1.6
Gross Margin
3.0
Operating Margin
4.1
Moat
5.0
Piotroski F
6.7
Current Ratio
9.3
No competitive moat
GatesMomentum 3.5<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 6d<=7dA.R:R 2.9 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
61 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $10.40Resistance $12.13

Price Targets

$11
$14
A.Upside+26.6%
A.R:R2.9:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.7 < 4.0)
! Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap)
! Momentum score 3.5/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PRGO stock a buy right now?

Sell if holding. Engine safety override at $11.41: Quality below floor (3.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 61. Prior stop was $10.64. Score 5.3/10, moderate confidence.

What is the PRGO stock price target?

Take-profit target: $14.45 (+26.3% upside). Prior stop was $10.64. Stop-loss: $10.64.

What are the risks of investing in PRGO?

Quality below floor (3.7 < 4.0); Value-trap signals (3/5): Revenue declining (-22.7% YoY), Margin compression (op margin -49.6%), Material insider selling (27 sells, 0.16% of cap).

Is PRGO overvalued or undervalued?

Perrigo Company plc trades at a P/E of N/A (forward 4.7). TrendMatrix value score: 9.3/10. Verdict: Sell.

What do analysts say about PRGO?

10 analysts cover PRGO with a consensus score of 3.8/5. Average price target: $17.

What does Perrigo Company plc do?Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and...

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Related stocks: INDV (Indivior Pharmaceuticals, Inc.) · NBIX (Neurocrine Biosciences, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.) · COLL (Collegium Pharmaceutical, Inc.) · ANIP (ANI Pharmaceuticals, Inc.)